SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of ca...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10230/34552 |
| Acceso en línea: | http://hdl.handle.net/10230/34552 http://dx.doi.org/10.1007/s12094-017-1763-6 |
| Access Level: | acceso abierto |
| Palabra clave: | Glioblastoma multiforme Diagnosis Glioblastoma Guidelines Treatment |
| id |
ES_5148e8fdf5d5fcbeaffc9c62e375aaf8 |
|---|---|
| oai_identifier_str |
oai:recercat.cat:10230/34552 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)Martínez-García, MariaÁlvarez-Linera, JuanCarrato, CristinaLey, L.Luque, RaquelMaldonado, X.Martínez-Aguillo, M.Navarro, L.M.Vaz-Salgado, M.A.Gil-Gil, Miguel J.Glioblastoma multiformeDiagnosisGlioblastomaGuidelinesTreatmentGlioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life.SpringerOpen201820182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/34552http://dx.doi.org/10.1007/s12094-017-1763-6reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésClinical and Translational Oncology. 2018 Jan;20(1):22-8This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/345522026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| title |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| spellingShingle |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) Martínez-García, Maria Glioblastoma multiforme Diagnosis Glioblastoma Guidelines Treatment |
| title_short |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| title_full |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| title_fullStr |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| title_full_unstemmed |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| title_sort |
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) |
| dc.creator.none.fl_str_mv |
Martínez-García, Maria Álvarez-Linera, Juan Carrato, Cristina Ley, L. Luque, Raquel Maldonado, X. Martínez-Aguillo, M. Navarro, L.M. Vaz-Salgado, M.A. Gil-Gil, Miguel J. |
| author |
Martínez-García, Maria |
| author_facet |
Martínez-García, Maria Álvarez-Linera, Juan Carrato, Cristina Ley, L. Luque, Raquel Maldonado, X. Martínez-Aguillo, M. Navarro, L.M. Vaz-Salgado, M.A. Gil-Gil, Miguel J. |
| author_role |
author |
| author2 |
Álvarez-Linera, Juan Carrato, Cristina Ley, L. Luque, Raquel Maldonado, X. Martínez-Aguillo, M. Navarro, L.M. Vaz-Salgado, M.A. Gil-Gil, Miguel J. |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Glioblastoma multiforme Diagnosis Glioblastoma Guidelines Treatment |
| topic |
Glioblastoma multiforme Diagnosis Glioblastoma Guidelines Treatment |
| description |
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life. |
| publishDate |
2017 |
| dc.date.none.fl_str_mv |
2017 2018 2018 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/34552 http://dx.doi.org/10.1007/s12094-017-1763-6 |
| url |
http://hdl.handle.net/10230/34552 http://dx.doi.org/10.1007/s12094-017-1763-6 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Clinical and Translational Oncology. 2018 Jan;20(1):22-8 |
| dc.rights.none.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
SpringerOpen |
| publisher.none.fl_str_mv |
SpringerOpen |
| dc.source.none.fl_str_mv |
reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869407946408984576 |
| score |
15,81155 |